{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:03:30Z","timestamp":1794344610520,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Mark Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41418-024-01439-7","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T21:31:13Z","timestamp":1734730273000},"page":"855-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state"],"prefix":"10.1038","volume":"32","author":[{"given":"Fleur","family":"Jochems","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysiida","family":"Baltira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9288-2722","authenticated-orcid":false,"given":"Julie A.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2812-991X","authenticated-orcid":false,"given":"Mark C.","family":"de Gooijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1037-6269","authenticated-orcid":false,"given":"Olaf","family":"van Tellingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-9013","authenticated-orcid":false,"given":"Anthony","family":"Letai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-3423","authenticated-orcid":false,"given":"Ren\u00e9","family":"Bernards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"1439_CR1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340\u201355.","journal-title":"Nat Rev Cancer"},{"key":"1439_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-022-10073-z","volume":"42","author":"K Truskowski","year":"2023","unstructured":"Truskowski K, Amend SR, Pienta KJ. Dormant cancer cells: programmed quiescence, senescence, or both? Cancer Metastasis Rev. 2023;42:37\u201347.","journal-title":"Cancer Metastasis Rev"},{"key":"1439_CR3","doi-asserted-by":"crossref","unstructured":"Soto-gamez A, Quax WJ, Demaria M. Regulation of survival networks in senescent cells: from mechanisms to interventions. J Mol Biol. 2019;431:2629\u201343.","DOI":"10.1016\/j.jmb.2019.05.036"},{"key":"1439_CR4","doi-asserted-by":"crossref","unstructured":"Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585\u2013621.","DOI":"10.1016\/0014-4827(61)90192-6"},{"key":"1439_CR5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.trsl.2020.06.007","volume":"226","author":"J Kaur","year":"2020","unstructured":"Kaur J, Farr JN. Cellular senescence in age-related disorders. Transl Res. 2020;226:96\u2013104.","journal-title":"Transl Res"},{"key":"1439_CR6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","volume":"436","author":"C Michaloglou","year":"2005","unstructured":"Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, Van Der Horst CMAM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720\u20134.","journal-title":"Nature"},{"key":"1439_CR7","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/jnci\/djq364","volume":"102","author":"JA Ewald","year":"2010","unstructured":"Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Institute. 2010;102:1536\u201346.","journal-title":"J Natl Cancer Institute"},{"key":"1439_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13051118","volume":"13","author":"G De Conti","year":"2021","unstructured":"De Conti G, Dias MH, Bernards R. Fighting drug resistance through the targeting of drug\u2010tolerant persister cells. Cancers. 2021;13:1\u201315.","journal-title":"Cancers"},{"key":"1439_CR9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.aaw1299","volume":"364","author":"JM Van Deursen","year":"2019","unstructured":"Van Deursen JM. Senolytic therapies for healthy longevity. Science. 2019;364:636\u20138.","journal-title":"Science"},{"key":"1439_CR10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria M, O\u2019Leary MN, Chang J, Shao L, Liu S, Alimirah F, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7:165\u201376.","journal-title":"Cancer Discov"},{"key":"1439_CR11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/acel.12445","volume":"15","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15:428\u201335.","journal-title":"Aging Cell"},{"key":"1439_CR12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"Chang J, Wang Y, Shao L, Laberge R-M, Demaria M, Campisi J, et al. Clearance of senescent cells by ABT-263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016;22:78\u201383.","journal-title":"Nat Med"},{"key":"1439_CR13","doi-asserted-by":"crossref","unstructured":"Yosef R, Pilpel N, Tokarsky-Amiel R, Biran A, Ovadya Y, Cohen S, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun. 2016;7:11190.","DOI":"10.1038\/ncomms11190"},{"key":"1439_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13030386","volume":"13","author":"J Lafontaine","year":"2021","unstructured":"Lafontaine J, Cardin GB, Malaquin N, Boisvert JS, Rodier F, Wong P. Senolytic targeting of bcl-2 anti-apoptotic family increases cell death in irradiated sarcoma cells. Cancers. 2021;13:1\u201320.","journal-title":"Cancers"},{"key":"1439_CR15","doi-asserted-by":"crossref","unstructured":"Shahbandi A, Rao SG, Anderson AY, Frey WD, Olayiwola JO, Ungerleider NA, et al. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. Cell Death Differ. 2020;27:3097\u2013116.","DOI":"10.1038\/s41418-020-0564-6"},{"key":"1439_CR16","doi-asserted-by":"crossref","first-page":"109441","DOI":"10.1016\/j.celrep.2021.109441","volume":"36","author":"F Jochems","year":"2021","unstructured":"Jochems F, Thijssen B, De Conti G, Jansen R, Pogacar Z, Groot K, et al. The cancer SENESCopedia: a delineation of cancer cell senescence. Cell Rep. 2021;36:109441.","journal-title":"Cell Rep"},{"key":"1439_CR17","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1111\/febs.13714","volume":"283","author":"KA Sarosiek","year":"2016","unstructured":"Sarosiek KA, Letai A. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics \u2013 recent successes, current challenges and future promise. FEBS J. 2016;283:3523\u201333.","journal-title":"FEBS J"},{"key":"1439_CR18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2017","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2017;25:65\u201380.","journal-title":"Cell Death Differ"},{"key":"1439_CR19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrm2312","volume":"9","author":"RC Taylor","year":"2008","unstructured":"Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231\u201341.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1439_CR20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"V Del Gaizo Moore","year":"2013","unstructured":"Del Gaizo Moore V, Letai A. BH3 profiling - Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332:202\u20135.","journal-title":"Cancer Lett"},{"key":"1439_CR21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1515\/hsz-2016-0107","volume":"397","author":"J Ryan","year":"2016","unstructured":"Ryan J, Montero J, Rocco J, Letai A. IBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;397:671\u20138.","journal-title":"Biol Chem"},{"key":"1439_CR22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160:977\u201389.","journal-title":"Cell"},{"key":"1439_CR23","first-page":"1","volume":"10","author":"L Hu","year":"2022","unstructured":"Hu L, Li H, Zi M, Li W, Liu J, Yang Y, et al. Why senescent cells are resistant to apoptosis: an insight for senolytic development. Front Cell Dev Biol. 2022;10:1\u201317.","journal-title":"Front Cell Dev Biol"},{"key":"1439_CR24","doi-asserted-by":"crossref","unstructured":"Martini H, Passos JF. Cellular senescence: all roads lead to mitochondria. FEBS J. 2022;290:1186\u2013202.","DOI":"10.1111\/febs.16361"},{"key":"1439_CR25","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/1878-0261.12761","volume":"14","author":"T Saleh","year":"2020","unstructured":"Saleh T, Carpenter VJ, Tyutyunyk-Massey L, Murray G, Leverson JD, Souers AJ, et al. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL\u2013BAX interaction. Mol Oncol. 2020;14:2504\u201319.","journal-title":"Mol Oncol"},{"key":"1439_CR26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1074\/jbc.RA118.004712","volume":"294","author":"SS Gayle","year":"2019","unstructured":"Gayle SS, Sahni JM, Webb BM, Weber-Bonk KL, Shively MS, Spina R, et al. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. J Biol Chem. 2019;294:875\u201386.","journal-title":"J Biol Chem"},{"key":"1439_CR27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.15252\/embj.201488806","volume":"34","author":"F Todt","year":"2015","unstructured":"Todt F, Cakir Z, Reichenbach F, Emschermann F, Lauterwasser J, Kaiser A, et al. Differential retrotranslocation of mitochondrial Bax and Bak. EMBO J. 2015;34:67\u201380.","journal-title":"EMBO J"},{"key":"1439_CR28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cell.2011.02.034","volume":"145","author":"F Edlich","year":"2011","unstructured":"Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, Wang C, et al. BCL-XL retrotranslocates BAX from the mitochondria into the cytosol. Cell. 2011;145:104\u201316.","journal-title":"Cell"},{"key":"1439_CR29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.molcel.2011.10.001","volume":"44","author":"F Llambi","year":"2011","unstructured":"Llambi F, Moldoveanu T, Tait SWG, Bouchier-Hayes L, Temirov J, McCormick LL, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell. 2011;44:517\u201331.","journal-title":"Mol. Cell"},{"key":"1439_CR30","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.272.21.13829","volume":"272","author":"YT Hsu","year":"1997","unstructured":"Hsu YT, Youle RJ. Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem. 1997;272:13829\u201334.","journal-title":"J Biol Chem"},{"key":"1439_CR31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bbrc.2011.08.118","volume":"413","author":"P Gomex-Bougie","year":"2011","unstructured":"Gomex-Bougie P, M\u00e9noret E, Juin P, Dousset C, Pellat-Deceunynck C, Amiot M. Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1\/USP9X. Biochem Biophys Res Commun. 2011;413:460\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"1439_CR32","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1073\/pnas.0701297104","volume":"104","author":"PE Czabotar","year":"2007","unstructured":"Czabotar PE, Lee EF, Van Delft MF, Day CL, Smith BJ, Huang DCS, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc. Natl Acad. Sci. USA. 2007;104:6217\u201322.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1439_CR33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","volume":"12","author":"J Deng","year":"2007","unstructured":"Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007;12:171\u201385.","journal-title":"Cancer Cell"},{"key":"1439_CR34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.22.00304","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A. Apoptosis: directly targeted at last. J Clin Oncol. 2022;40:1693\u20135.","journal-title":"J Clin Oncol"},{"key":"1439_CR35","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.275.5302.967","volume":"275","author":"N Rampino","year":"1997","unstructured":"Rampino N, Yamamoto H, Li Y, Sawai H, Reed JC, Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275:967\u20139.","journal-title":"Science"},{"key":"1439_CR36","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","volume":"185","author":"R Pan","year":"2022","unstructured":"Pan R, Ryan J, Pan D, Wucherpfennig KW, Letai A. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022;185:1521\u201338.e1518.","journal-title":"Cell"},{"key":"1439_CR37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","volume":"38","author":"S Bhatt","year":"2020","unstructured":"Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell. 2020;38:872\u201390.","journal-title":"Cancer Cell"},{"key":"1439_CR38","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1038\/s41467-022-35657-9","volume":"13","author":"J Kohli","year":"2022","unstructured":"Kohli J, Ge C, Fitsiou E, Doepner M, Brandenburg SM, Faller WJ, et al. Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression. Nat Commun. 2022;13:7923.","journal-title":"Nat Commun"},{"key":"1439_CR39","first-page":"1","volume":"13","author":"B Wang","year":"2014","unstructured":"Wang B, Ni Z, Dai X, Qin L, Li X, Xu L, et al. The Bcl-2\/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer. 2014;13:1\u201311.","journal-title":"Mol Cancer"},{"key":"1439_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01007-9","volume":"13","author":"A Bolomsky","year":"2020","unstructured":"Bolomsky A, Vogler M, K\u00f6se MC, Heckman CA, Ehx G, Ludwig H, et al. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol. 2020;13:1\u201319.","journal-title":"J Hematol Oncol"},{"key":"1439_CR41","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.molcel.2024.02.035","volume":"84","author":"T Wright","year":"2024","unstructured":"Wright T, Turnis ME, Grace CR, Li X, Brakefield LA, Wang YD, et al. Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1. Mol Cell. 2024;84:1338\u20131353.e1338.","journal-title":"Mol Cell"},{"key":"1439_CR42","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s43018-024-00814-0","volume":"5","author":"U Rauh","year":"2024","unstructured":"Rauh U, Wei G, Serrano-Wu M, Kosmidis G, Kaulfuss S, Siegel F, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nat Cancer. 2024;5:1479\u201393.","journal-title":"Nat Cancer"},{"key":"1439_CR43","doi-asserted-by":"crossref","unstructured":"He Y, Zhang X, Chang J, Kim HN, Zhang P, Wang Y, et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 2020;11:1996.","DOI":"10.1038\/s41467-020-15838-0"},{"key":"1439_CR44","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347.","journal-title":"Nat Med"},{"key":"1439_CR45","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Gualda E, P\u00e0ez-Ribes M, Lozano-Torres B, Macias D, Wilson JR, Gonz\u00e1lez-L\u00f3pez C, et al. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. Aging Cell 2020;19:e13142.","DOI":"10.1111\/acel.13142"},{"key":"1439_CR46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","volume":"151","author":"TT Vo","year":"2012","unstructured":"Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012;151:344\u201355.","journal-title":"Cell"},{"key":"1439_CR47","doi-asserted-by":"crossref","unstructured":"Potter DS, Du R, Bhola P, Bueno R, Letai A. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. Cell Death Dis. 2021;12:741.","DOI":"10.1038\/s41419-021-04029-4"},{"key":"1439_CR48","doi-asserted-by":"crossref","unstructured":"Hughes DL, Hughes A, Soonawalla Z, Mukherjee S, O\u2019neill E. Dynamic physiological culture of ex vivo human tissue: a systematic review. Cancers 2021;13:2870.","DOI":"10.3390\/cancers13122870"},{"key":"1439_CR49","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ijc.32639","volume":"146","author":"T Robin","year":"2020","unstructured":"Robin T, Capes-Davis A, Bairoch A. CLASTR: the Cellosaurus STR similarity search tool - A precious help for cell line authentication. Int JCancer. 2020;146:1299\u2013306.","journal-title":"Int JCancer"},{"key":"1439_CR50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ymeth.2013.04.006","volume":"61","author":"A Letai","year":"2013","unstructured":"Letai A, Ryan J. BH3 profiling in whole cells by fluorimeter or FACS. Methods. 2013;61:156\u201364.","journal-title":"Methods"},{"key":"1439_CR51","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413\u20135.","journal-title":"Bioinformatics"}],"container-title":["Cell Death & Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-024-01439-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-024-01439-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-024-01439-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:06:08Z","timestamp":1747641968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-024-01439-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1038\/s41418-024-01439-7","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RB is co-founder of Oncosence BV, Chief Scientific Officer at Agendia Inc., and board member of Lixte Biotechnology Holdings, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}